See more : Northern Genesis Acquisition Corp. III (NGC-UN) Income Statement Analysis – Financial Results
Complete financial analysis of Applied Genetic Technologies Corporation (AGTC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Applied Genetic Technologies Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
- Equifax Inc. (EFX) Income Statement Analysis – Financial Results
- Stevia Nutra Corp (STNT) Income Statement Analysis – Financial Results
- Dynamic Technologies Group Inc. (DTG.V) Income Statement Analysis – Financial Results
- Prairie Operating Co. (PROP) Income Statement Analysis – Financial Results
- First High-School Education Group Co., Ltd. (FHS) Income Statement Analysis – Financial Results
Applied Genetic Technologies Corporation (AGTC)
About Applied Genetic Technologies Corporation
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 325.00K | 500.00K | 2.45M | 41.69M | 24.19M | 39.47M | 47.36M | 2.35M | 1.13M | 942.00K | 1.08M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 325.00K | 500.00K | 2.45M | 41.69M | 24.19M | 39.47M | 47.36M | 2.35M | 1.13M | 942.00K | 1.08M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 49.52M | 44.40M | 35.78M | 33.18M | 32.18M | 26.22M | 38.86M | 16.53M | 8.50M | 3.13M | 2.35M |
| General & Administrative | 16.99M | 14.55M | 13.62M | 12.86M | 14.39M | 11.35M | 10.59M | 10.36M | 5.18M | 1.40M | 787.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 16.99M | 14.55M | 13.62M | 12.86M | 14.39M | 11.35M | 10.59M | 10.36M | 5.18M | 1.40M | 787.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 66.50M | 58.95M | 49.40M | 46.04M | 46.57M | 37.57M | 49.45M | 26.89M | 13.69M | 4.54M | 3.14M |
| Cost & Expenses | 66.50M | 58.95M | 49.40M | 46.04M | 46.57M | 37.57M | 49.45M | 26.89M | 13.69M | 4.54M | 3.14M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 42.00K | 0.00 | 0.00 |
| Interest Expense | 2.67M | 1.51M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 191.00K | 69.00K |
| Depreciation & Amortization | 1.51M | 1.46M | 1.34M | 1.27M | 1.18M | 912.00K | 567.00K | 376.00K | 334.00K | 285.00K | 262.00K |
| EBITDA | -64.76M | -56.97M | -46.94M | -4.35M | -20.05M | 3.72M | -814.00K | -24.53M | -12.56M | -4.51M | -1.59M |
| EBITDA Ratio | -19,925.23% | -11,394.20% | -1,813.05% | -1.58% | -82.91% | 9.42% | -1.72% | -1,017.08% | -1,379.45% | -479.19% | -147.23% |
| Operating Income | -66.27M | -58.45M | -46.94M | -4.35M | -22.38M | 1.90M | -2.09M | -24.53M | -12.56M | -3.59M | -2.06M |
| Operating Income Ratio | -20,390.46% | -11,690.20% | -1,913.66% | -10.43% | -92.55% | 4.82% | -4.41% | -1,042.14% | -1,112.13% | -381.53% | -190.30% |
| Total Other Income/Expenses | -2.58M | -1.39M | 1.18M | 2.46M | 1.18M | 905.00K | 708.00K | 214.00K | -3.35M | -1.40M | 135.00K |
| Income Before Tax | -68.75M | -59.84M | -45.76M | -1.90M | -21.21M | 2.81M | -1.38M | -24.32M | -15.91M | -4.99M | -1.92M |
| Income Before Tax Ratio | -21,153.85% | -11,968.20% | -1,865.55% | -4.55% | -87.69% | 7.11% | -2.92% | -1,033.05% | -1,409.03% | -529.72% | -177.82% |
| Income Tax Expense | 2.67M | -2.11M | 83.00K | 76.00K | 72.00K | 2.40M | 708.00K | 214.00K | -3.35M | -1.21M | 204.00K |
| Net Income | -71.42M | -57.83M | -45.89M | -2.01M | -21.30M | 407.00K | -1.38M | -24.32M | -15.91M | -4.99M | -1.92M |
| Net Income Ratio | -21,976.62% | -11,565.80% | -1,870.85% | -4.81% | -88.07% | 1.03% | -2.92% | -1,033.05% | -1,409.03% | -529.72% | -177.82% |
| EPS | -1.59 | -1.77 | -2.17 | -0.11 | -1.18 | 0.02 | -0.08 | -1.50 | -4.46 | -1.20 | -0.28 |
| EPS Diluted | -1.59 | -1.77 | -2.17 | -0.11 | -1.18 | 0.02 | -0.08 | -1.50 | -4.46 | -1.20 | -0.28 |
| Weighted Avg Shares Out | 45.03M | 32.76M | 21.10M | 18.16M | 18.11M | 18.07M | 17.81M | 16.25M | 3.57M | 4.15M | 6.89M |
| Weighted Avg Shares Out (Dil) | 45.03M | 32.76M | 21.10M | 18.16M | 18.11M | 18.39M | 17.81M | 16.25M | 3.57M | 4.15M | 6.89M |
Beyondspring (BYSI) Gets a Buy Rating from H.C. Wainwright
Analysts Are Bullish on These Healthcare Stocks: Aptinyx (APTX), Iovance Biotherapeutics (IOVA)
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Novavax (NVAX)
Analysts Conflicted on These Healthcare Names: TG Therapeutics (TGTX), Co-Diagnostics (CODX) and PDS Biotechnology (PDSB)
Analysts Offer Insights on Healthcare Companies: Zosano Pharma (ZSAN), Principia Biopharma (PRNB) and Nabriva (NBRV)
Analysts Offer Insights on Healthcare Companies: Provention Bio (PRVB) and ACADIA Pharmaceuticals (ACAD)
H.C. Wainwright Thinks IMV's Stock is Going to Recover
Analysts Are Bullish on These Healthcare Stocks: Motus Gi Holdings (MOTS), Cytokinetics (CYTK)
Beyondspring (BYSI) Gets a Buy Rating from H.C. Wainwright
H.C. Wainwright Sticks to Their Buy Rating for Beyondspring (BYSI)
Source: https://incomestatements.info
Category: Stock Reports